Key Metrics
CiteScore 

1
SNIP 

0.35
Recommended pre-submission checks
Powered by 

Crohn's and Colitis 360 Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
DOAJ
SJR
| Overview | |
| Publisher | OXFORD UNIV PRESS |
| Language | English |
| Frequency | Quarterly |
| Article Processing Charges | USD 2975 |
| Publication Time | 12 |
| Editorial Review Process | Double anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | Crohn's and Colitis Foundation |
| Frequency | Quarterly |
| Publication Start Year | 2019 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Crohn's and Colitis 360 ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Crohn's and Colitis 360
Comparative effectiveness of low versus high dose upadacitinib as maintenance treatment in patients with ulcerative colitis: a real-world cohort study from the United States
- 8 May 2026
- 1 Jan 0360
Racial disparities in prevalence, screening, and complications of osteoporosis in patients with inflammatory bowel disease: a retrospective cohort study
- 26 Apr 2026
- 1 Jan 0360
Prevalence, age-distribution, and impact on management of acne in patients on upadacitinib for inflammatory bowel disease: insights from a single-center survey
- 24 Apr 2026
- 1 Jan 0360
Evaluation of a pharmacist directed treat to target approach in patients with inflammatory bowel disease receiving upadacitinib or risankizumab
- 20 Apr 2026
- 1 Jan 0360
Providing care at a most vulnerable time.
- 11 Apr 2026
- 1 Jan 0360
Comparison of IBD-related outcomes in patients with obesity treated with GLP-1 receptor agonists versus bariatric surgery.
- 1 Apr 2026
- 1 Jan 0360
Comparative effectiveness of low versus high dose upadacitinib as maintenance treatment in patients with ulcerative colitis: a real-world cohort study from the United States
- 8 May 2026
- 1 Jan 0360
Racial disparities in prevalence, screening, and complications of osteoporosis in patients with inflammatory bowel disease: a retrospective cohort study
- 26 Apr 2026
- 1 Jan 0360
Prevalence, age-distribution, and impact on management of acne in patients on upadacitinib for inflammatory bowel disease: insights from a single-center survey
- 24 Apr 2026
- 1 Jan 0360
Evaluation of a pharmacist directed treat to target approach in patients with inflammatory bowel disease receiving upadacitinib or risankizumab
- 20 Apr 2026
- 1 Jan 0360
Providing care at a most vulnerable time.
- 11 Apr 2026
- 1 Jan 0360
Comparison of IBD-related outcomes in patients with obesity treated with GLP-1 receptor agonists versus bariatric surgery.
- 1 Apr 2026
- 1 Jan 0360